{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T22:58:28Z","timestamp":1778021908464,"version":"3.51.4"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1588,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1111\/j.1365-2516.2011.02534.x","type":"journal-article","created":{"date-parts":[[2011,4,28]],"date-time":"2011-04-28T02:58:34Z","timestamp":1303959514000},"page":"895-905","source":"Crossref","is-referenced-by-count":56,"title":["von Willebrand factor\/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease"],"prefix":"10.1111","volume":"17","author":[{"given":"J. C.","family":"GILL","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"SHAPIRO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. A.","family":"VALENTINO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"BERNSTEIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"FRIEDMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. L.","family":"NICHOLS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"MANCO-JOHNSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,4,27]]},"reference":[{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1351-8216.2003.00816.x","article-title":"Successful treatment of urgent bleeding in von Willebrand disease with factor VIII\/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy","volume":"9","author":"Gill","year":"2003","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB2|cit2","first-page":"233","article-title":"Molecular and cellular biology of von Willebrand factor","volume":"9","author":"Handin","year":"1989","journal-title":"Prog Hemost Thromb"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V58.1.1.1","article-title":"The factor VIII complex: structure and function","volume":"58","author":"Hoyer","year":"1981","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s002770050184","article-title":"Von Willebrand factor: molecular size and functional activity","volume":"72","author":"Furlan","year":"1996","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0308-2261(21)00379-9","article-title":"von Willebrand\u2019s disease","volume":"12","author":"Zimmerman","year":"1983","journal-title":"Clin Haematol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V69.2.454.454","article-title":"Epidemiological investigation of the prevalence of von Willebrand\u2019s disease","volume":"69","author":"Rodeghiero","year":"1987","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000214857","article-title":"Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings","volume":"121","author":"Michiels","year":"2009","journal-title":"Acta Haematol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/00000658-197912000-00014","article-title":"Surgery in von Willebrand\u2019s disease","volume":"190","author":"Nilsson","year":"1979","journal-title":"Ann Surg"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2516.2007.01643.x","article-title":"von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)","volume":"14","author":"Nichols","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/j.1538-7836.2007.02588.x","article-title":"von Willebrand factor\/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery","volume":"5","author":"Lethagen","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1055\/s-0037-1612977","article-title":"Efficacy and safety of the factor VIII\/von Willebrand factor concentrate, haemate-P\/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease","volume":"87","author":"Lillicrap","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1182\/blood.V99.2.450","article-title":"Treatment of von Willebrand disease with a high-purity factor VIII\/von Willebrand factor concentrate: a prospective, multicenter study","volume":"99","author":"Mannucci","year":"2002","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1365-2516.2008.01784.x","article-title":"Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII\/VWF concentrate","volume":"14","author":"Hernandez-Navarro","year":"2008","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-0609.1988.tb00825.x","article-title":"Biochemical and in vivo properties of commercial virus-inactivated factor VIII concentrates","volume":"40","author":"Berntorp","year":"1988","journal-title":"Eur J Haematol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2141.1989.tb00227.x","article-title":"Comparison of the in vitro characteristics of von Willebrand factor in British and commercial factor VIII concentrates","volume":"73","author":"Lawrie","year":"1989","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra040403","article-title":"Treatment of von Willebrand\u2019s Disease","volume":"351","author":"Mannucci","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB17|cit17","first-page":"1279","article-title":"Efficacy and safety of factor VIII\/von Willebrand\u2019s factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease","volume":"88","author":"Franchini","year":"2003","journal-title":"Haematologica"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1351-8216.2003.00809.x","article-title":"Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII\/VWF concentrate (Humate-P)","volume":"10","author":"Thompson","year":"2004","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.1423-0410.1989.tb02031.x","article-title":"Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand\u2019s disease","volume":"56","author":"Berntorp","year":"1989","journal-title":"Vox Sang"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB20|cit20","first-page":"298","article-title":"Experience with Haemate P in von Willebrand\u2019s disease in adults","volume":"24","author":"Scharrer","year":"1994","journal-title":"Haemostasis"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/BF00320748","article-title":"Hemostatic effect of a heat-treated factor VIII concentrate (Haemate P) in von Willebrand\u2019s disease","volume":"56","author":"Fukui","year":"1988","journal-title":"Blut"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB22|cit22","first-page":"304","article-title":"Haemate P in children with von Willebrand\u2019s disease","volume":"24","author":"Kreuz","year":"1994","journal-title":"Haemostasis"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1046\/j.1537-2995.1990.30490273452.x","article-title":"Correction of prolonged bleeding time in von Willebrand\u2019s disease with Humate-P","volume":"30","author":"Rose","year":"1990","journal-title":"Transfusion (Paris)"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ajh.2830300305","article-title":"Evaluation of factor VIII pharmacokinetics in hemophilia-A subjects undergoing surgery and description of a nomogram for dosing calculations","volume":"30","author":"Longo","year":"1989","journal-title":"Am J Hematol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/ajcp\/63.2.210","article-title":"Evaluation of ristocetin-Willebrand factor assay and ristocetin-induced platelet aggregation","volume":"63","author":"Olson","year":"1975","journal-title":"Am J Clin Pathol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1538-7836.2008.02845.x","article-title":"A highly-sensitive plasma von Willebrand factor ristocetin cofactor (VWF:RCo) activity assay by flow cytometry","volume":"6","author":"Chen","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.thromres.2010.09.015","article-title":"Plasma von Willebrand factor multimer quantitative analysis by in-gel immunostaining and infrared fluorescent imaging","volume":"126","author":"Pruthi","year":"2010","journal-title":"Thromb Res"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1172\/JCI109795","article-title":"Variant von Willebrand\u2019s disease: characterization of two subtypes by analysis of multimeric composition of factor VIII\/von Willebrand factor in plasma and platelets","volume":"65","author":"Ruggeri","year":"1980","journal-title":"J Clin Invest"},{"issue":"Suppl. 3","key":"10.1111\/j.1365-2516.2011.02534.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x","article-title":"Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease","volume":"4","author":"Dobrkovska","year":"1998","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1111\/j.1538-7836.2005.01435.x","article-title":"Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation\/removal methods","volume":"3","author":"Goudemand","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01836069","article-title":"Pharmacokinetics and hemostatic effect of different factor VIII\/von Willebrand factor concentrates in von Willebrand\u2019s disease type III","volume":"65","author":"Lethagen","year":"1992","journal-title":"Ann Hematol"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB32|cit32","first-page":"173","article-title":"The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease","volume":"71","author":"Hanna","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00001721-200406000-00006","article-title":"Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P)","volume":"15","author":"Michiels","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2516.2010.02239.x","article-title":"BDDrFVIII (Moroctocog alfa [AF-CC]) for surgical haemostasis in patients with haemophilia A: results of a pivotal study","volume":"16","author":"Windyga","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1160\/TH05-01-0013","article-title":"Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII?","volume":"93","author":"Wells","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0140-6736(95)90166-3","article-title":"Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis","volume":"345","author":"Koster","year":"1995","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2011.02534.x-BIB38|cit38","volume-title":"Full Prescribing Information","author":"Humate-P (VWF\/FVIII concentrate)","year":"2007"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2011.02534.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2516.2011.02534.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T08:57:21Z","timestamp":1637571441000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2011.02534.x"}},"subtitle":["VWF\/FVIII CONCENTRATE IN ELECTIVE SURGERY"],"short-title":[],"issued":{"date-parts":[[2011,4,27]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,11]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2011.02534.x","relation":{},"ISSN":["1351-8216"],"issn-type":[{"value":"1351-8216","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4,27]]}}}